Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exploring the limits of cyanobactin macrocyclase PatGmac: Cyclization of PawS-derived peptide sunflower trypsin inhibitor-1 and cyclotide kalata B1
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. (Farmakognosi)ORCID iD: 0000-0002-6636-5809
Department of Chemistry, Marine Biodiscovery Centre, University of Aberdeen, Aberdeen AB243UE, Scotland, UK..
Department of Chemistry, Marine Biodiscovery Centre, University of Aberdeen, Aberdeen AB243UE, Scotland, UK..
Centre, University of Aberdeen, Aberdeen AB243UE, Scotland, UK..
Show others and affiliations
2023 (English)In: Journal of Natural Products, ISSN 0974-5211, Vol. 86, no 3, p. 566-573Article in journal (Refereed) Published
Abstract [en]

The subtilisin-like macrocyclase PatGmac is produced by the marine cyanobacterium Prochloron didemni. This enzyme is involved in the last step of the biosynthesis of patellamides, a cyanobactin type of ribosomally expressed and post-translationally modified cyclic peptides. PatGmac recognizes, cleaves, and cyclizes precursor peptides after a specific recognition motif comprised of a C-terminal tail with the sequence motif -AYDG. The result is the native macrocyclic patellamide, which has eight amino acid residues. Macrocyclase activity can be exploited by incorporating that motif in other short linear peptide precursors, which then are formed into head-to-tail cyclized peptides. Here, we explore the possibility of using PatGmac in the cyclization of peptides larger than the patellamides, namely, the PawS-derived peptide sunflower trypsin inhibitor-1 (SFTI-1) and the cyclotide kalata B1. These peptides fall under two distinct families of disulfide constrained macrocyclic plant peptides. They are both implicated as scaffolds for drug design due to their structures and unusual stability. We show that PatGmac can be used to efficiently cyclize the 14 amino acid residue long SFTI-1, but less so the 29 amino acid residue long kalata B1.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2023. Vol. 86, no 3, p. 566-573
National Category
Pharmaceutical Sciences
Research subject
Pharmacognosy
Identifiers
URN: urn:nbn:se:uu:diva-397023DOI: 10.1021/acs.jnatprod.2c01158ISI: 000953940600001PubMedID: 36917740OAI: oai:DiVA.org:uu-397023DiVA, id: diva2:1370056
Funder
Swedish Research Council Formas, 2016-01474Carl Tryggers foundation , CTS 10:216Available from: 2019-11-13 Created: 2019-11-13 Last updated: 2024-01-26Bibliographically approved
In thesis
1. LL-37-derived cyclic antimicrobial drug leads: Design, synthesis, activity and different ways of creating them 
Open this publication in new window or tab >>LL-37-derived cyclic antimicrobial drug leads: Design, synthesis, activity and different ways of creating them 
2019 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

In an era where last-line antibiotics are failing, one of the powerful approaches to develop novel therapeutic agents is to turn back to nature in order to identify possible drug candidates. Among the potential candidates, antimicrobial peptides (AMPs) have garnered much attention as an antimicrobial. These are broad spectrum host defense molecules produced by all living organisms. LL-37 is such a multitask human defense peptide that mediates various host immune responses and also exerts antimicrobial activity. However, the direct use of this 37-amino acid long α-helical peptide is hampered by protease susceptibility, in particular for antimicrobial applications. A small 12-residues peptide, referred as KR-12, derived from LL-37, has been reported to have selective toxic effect on bacteria. 

Analogues of KR-12 were generated in the form of Alanine and Lysine scans to find out the positions important for improved activity and selectivity. Backbone-cyclised dimers based on KR-12 and KR-12 analogues, tethered by linkers of two to four amino acid residues, were synthesised to explore the concept of cyclisation, dimerisation and cross-linking as means to enhance peptide stability and activity. Antimicrobial activities of the linear peptides and cyclic dimers were assayed against human pathogens, in buffer and/or physiological conditions. Proteolytic stability, permeabilisation efficacy on microbial membranes and, their structures were also characterised.  

From Ala and Lys scans, it was possible to identify two key positions for the enhanced broad-spectrum antibacterial activity: replacement of Gln5 with Lys, and Asp9 with either Ala or Lys. In serum stability assay, KR-12 and analogues were found to be unstable. The backbone-cyclised KR-12 dimers showed improved antimicrobial activity and increased stability compared to monomeric KR-12. KR-12 monomers adopt a well-defined α-helical structure in membrane-mimicking environment, while cyclised dimers were unstructured in solution judged by NMR. The KR-12 (Q5K, D9A) cyclised dimers retained antimicrobial activity in physiological conditions. Circular dichroism showed that the cyclic dimer, cd4-PP, had 77% helical content when bound to lyso-phosphatidylglycerol micelles.

Moreover, the limits of cyanobactin-macrocyclase PatGmac were explored to cyclise peptides larger than their natural substrates, namely the PawS derived peptide Sunflower Trypsin Inhibitor-1 (SFTI-1) and the cyclotide kalata B1. PatGmac was used very efficiently to cyclise SFTI-1. In addition, semi-pure butelase 1, isolated from Clitoria ternatea seeds, was immobilised on NHS column. The immobilised column was then used to produce substrates ranging from 16 to 34 varying length.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2019. p. 65
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 281
Keywords
antimicrobial peptide, host defense, antimicrobial, LL-37, KR-12, peptide cyclisation, peptide dimerisation, croos-linking, cyanobactin-macrocyclase, PatGmac, butelase 1, enzymatic cyclisation, immobilisation
National Category
Medical and Health Sciences
Research subject
Pharmacognosy
Identifiers
urn:nbn:se:uu:diva-397191 (URN)978-91-513-0813-5 (ISBN)
Public defence
2019-12-19, A1:107a, Biomedical Centrum (BMC), Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2019-11-27 Created: 2019-11-18 Last updated: 2020-01-13Bibliographically approved

Open Access in DiVA

fulltext(4139 kB)332 downloads
File information
File name FULLTEXT01.pdfFile size 4139 kBChecksum SHA-512
e0b3115f4979a078cdb9ee4988dbdc23232777e2e8726d9f98f50690a61f0502a60ca7ac689c3050a94b44b75eaa9d11d00bfbf45e53e07cc4a2c40e02ddb640
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Muhammad, TajGunasekera, SunithiGöransson, Ulf

Search in DiVA

By author/editor
Muhammad, TajGunasekera, SunithiGöransson, Ulf
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Journal of Natural Products
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 333 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 317 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf